查詢結果分析
來源資料
相關文獻
- 肝細胞癌之早期發現及其治療
- 甲種胎兒蛋白與肝細胞癌
- 南部地區國軍肝炎病毒血清標記盛行調查
- Metastatic Hepatocellular Carcinoma Presenting as Hemocholecyst with Perforation: A Case Report
- 天然產物抗人類肝細胞癌活性之研究:芸香科生物鹼之篩選
- 皮肌炎合併肝細胞癌: 一病例報告及文獻探討
- Fibrolamellar Hepatocellular Carcinoma: Report of Two Cases
- Presumed Choroid Metastasis from Hepatocellular Carcinoma: A Case Report
- 肝細胞癌(Hepatocellular Carcinoma)病理學診斷
- Dose-Volume Analysis for 4 Patients with Radiation-Induced Liver Disease after 3-Dimensional Conformal Radiotherapy for Hepatocellular Carcinoma
頁籤選單縮合
題 名 | 肝細胞癌之早期發現及其治療=Early Detection of Hepatocellular Carcinoma and Its Treatments |
---|---|
作 者 | 許金川; | 書刊名 | 內科學誌 |
卷 期 | 9:1 1998.03[民87.03] |
頁 次 | 頁1-6 |
分類號 | 415.5362 |
關鍵詞 | 肝細胞癌; 甲種胎兒蛋白; 超音波掃瞄術; Hepatocellular carcinoma; Alpha-fetoprotein; Ultrasonography; |
語 文 | 中文(Chinese) |
中文摘要 | 肝細胞癌(以下簡稱肝癌)是全世界最常見之癌症之一,也是國人癌症死因中男 性之第一位,女性之第二位。目前早期發現肝癌已非難事。針對肝癌之高危險群定期檢驗 血中之甲種胎兒蛋白及腹部超音波檢查,可以發現3公分以下之小型肝癌。高危險群包括 1)肝硬化病人(2)一及二等親中有肝癌家族史者(3)慢性B型肝炎、C型肝炎患者(4)B型肝炎 帶原者。約有三分之一的小型肝癌患者血清中甲種胎兒蛋白正常,也有少數之肝癌因位置 關係或回音相同而超音波不易診測,因此二者不可缺一。電腦斷層檢查及磁共振檢查對小 型肝癌之偵測誤失率較大而且昂貴,受時較久,血管攝影應保留於栓塞治療時或手術前之 評估之用。 小型肝癌之治療仍以外科切除預後較佳。十年存活率約百分之五十,但如多發性或肝 機能不佳,可用肝動脈栓塞術治療,如肝癌小於三公分且數目在三個以下,以超音波指引 行酒精注射也是另一替代方法。 小型肝癌治療後存活率欠佳之主要原因為肝癌容易再發,其次為患者大多合併肝硬化 ,可能因肝衰竭或食道靜脈瘤破裂而死。 整體而言,肝癌之早期發現至少有三分之一以上的病人幾可達痊癒之效果。其三分之 一可以延長其生命,其餘三分之一可能無實質上的益處。治療肝癌最佳之道在於B型肝炎 及C型肝炎感染之預防。對於肝功能不佳無法手術切除且不適合行栓塞治療及酒精注射之 患者,肝臟移植是另一可行之道。 |
英文摘要 | Hepatocellular carcinoma (HCC) is one of the most common malignancy in the world. In Taiwan, it is the leading cause of cancer mortality in male and second cause of cancer death for female. Before the era of early detection, most of the HCC patients died within 4 to 6 months after symptoms appeared. Chronic hepatitis B viral (HBV) infection is the major cause of hepatocarcinogenesis. About 15% to 20% of the general population in Taiwan were HBsAg carriers. The relative risk of developing HCC for HBsAg carriers than non-carriers is more than 150 fold. Hepatitis C viral infection is the second major cause of HCC. About 2- 4% of the general population were positive for HCV. The best method for early detection of small HCC (<3cm in diameter) is regular follow- up in high-risk subjects of HCC, including patients with liver cirrhosis, victims of chronic viral hepatitis, old hepatitis B carriers and those with family history of HCC, by serum alpha-fetoprotein ( AFP) and abdominal ultrasonography. About one third of small HCC has normal serum AFP level and some HCCs may be missec by ultrasound due to iso- echogenecity or special location. Therefore, combined. use of both diagnostic tools is necessary. The treatment of choice for small HCC is surgical resection. Transcatheter arterial emboliztaion can be used if operation is contraindicated due to poor liver reserve or multiplicity of the tumor number. Alcohol injection is another alternative in cases with tumors which are smaller than 3cm and less than 3 in number. Liven transplantation may become more important in furture for the treatment of HCC. The 1 0-year survival rate after surgical resection is about 50%. The major cause of death after surgical resection is tumor recurrence or due to hepatic failure or variceal bleeding resulting from the underlying liver cirrhosis. Eradication of the HBV and HCV infection and to prevent the development of liver cirrhosis are important for the prevention of this cancer. (J Intern Med Taiwan 1998; 9: 1-6) |
本系統中英文摘要資訊取自各篇刊載內容。